El Chaer, F., Rein, L. A. M., Yuda, J., Shimoda, K., Takami, A., Ichii, M., … Rampal, R. (2024). Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients. Blood, 144(Supplement 1), 655–655. https://doi.org/10.1182/blood-2024-200312

El Chaer, Firas, Lindsay A. M. Rein, Junichiro Yuda, Kazuya Shimoda, Akiyoshi Takami, Michiko Ichii, James McCloskey, et al. “Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients.” Blood 144, no. Supplement 1 (November 5, 2024): 655–655. https://doi.org/10.1182/blood-2024-200312.

El Chaer F, Rein LAM, Yuda J, Shimoda K, Takami A, Ichii M, et al. Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients. Blood. 2024 Nov 5;144(Supplement 1):655–655.

El Chaer, Firas, et al. “Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, Nov. 2024, pp. 655–655. Crossref, doi:10.1182/blood-2024-200312.

El Chaer F, Rein LAM, Yuda J, Shimoda K, Takami A, Ichii M, McCloskey J, Scandura JM, Iurlo A, Bose P, Haque T, Lucchesi A, Shirane S, Benevolo G, Amanam I, Kiladjian J-J, Vachhani P, Tantravahi SK, Onishi Y, Rinaldi C, Rotta M, Granacher N, Patel AA, Loschi M, Alimam S, Bradley T, Cheung S, Ribrag V, Kabir S, Ansaldo K, Seki M, Loksa V, Li Z, Foulks JM, Shah J, Rampal R. Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients. Blood. American Society of Hematology; 2024 Nov 5;144(Supplement 1):655–655.